Filing Flows › Tenaya Therapeutics (TNYA) › Q2 2026
Tenaya Therapeutics (TNYA) Q2 2026 earnings results (second quarter 2026)
10-Q filed Aug 5, 2026
Tenaya Therapeutics (TNYA) reported revenue of $1.1M for the second quarter 2026 (Q2 2026) and +393% from the quarter before.
Tenaya Therapeutics, Q2 2026: revenue $1.1M, net loss $43.4M, operating cash flow −$3.6M. The chart follows the revenue to costs, profit and cash.
| Q2 2026 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $1.1M | +393% | — |
| Operating profit | −$44.1M | — | — |
| Net earnings | −$43.4M | — | — |
| Operating cash flow | −$3.6M | — | — |
What changed
Revenue was $1.1M in Q2 2026, up 393% from the previous quarter.
Operating costs exceeded revenue by $44.1M, an operating margin of -3971.9%. The quarter ended with a net loss of $43.4M, wider than the previous quarter's $19.3M loss.
Operating cash flow was −$3.6M. Non-cash charges added back $1.7M of depreciation and amortization and $1.7M of share-based compensation. Working capital and other items added $36.4M. Capital expenditures of $159K exceeded it, leaving free cash flow of −$3.7M.
Questions
What was Tenaya Therapeutics' revenue in the second quarter 2026?
Tenaya Therapeutics (TNYA) reported revenue of $1.1M for the second quarter 2026 (Q2 2026) and +393% from the quarter before.